Drugs / BPR-6023021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07249892 | Nov 2025 → Jul 2027 expected | metastatic neoplasm | Chengdu Syncor Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPR-6023021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07249892 ↗ |
| Modality | Other / unclassified | “BPR-6023021 is a Radionuclide conjugated drugs (RDC) targeting bone.” NCT07249892 ↗ |